FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy

FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...

Life science trends 2025 – Part 1 obesity drugs

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

Non-destructive testing and assembly control

Assess complete assembly.

Meet us at Control 2025

Innovations that drive efficiency.

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Reduced heat transfer to the media with media-separated valves

In laboratory automation, many liquids are used that react sensitively to heat. One possible factor for the transfer of heat to the fluid are media-separated so...

Lilly recruits top Swedish researcher in Alzheimer´s

One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.

Try arivis for free

30-day free trial offers a number of benefits.

Digitala produktpass - från regelverk till konkurrensfördel

Inom EU pågår just nu en omfattande omställning mot mer cirkulära och hållbara affärsmodeller. En viktig pusselbit i detta arbete är införandet av digitala prod...

Norway rejects national life science strategy – sees no need

The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.

Ancient DNA provides new insights – “The immune system lost its job”

Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

Mastering Urine Microscopy: Techniques for Accurate Disease Detection

Live Webinar on September 25, 2024.

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.